X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to accelerate the completion of patient enrollment in the ongoing Phase 2 study of BioRestorative's primary clinical candidate, BRTX-100, for chronic lumbar disc disease.
Lead Product(s): BRTX-100
Therapeutic Area: Musculoskeletal Product Name: BRTX-100
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Galen Patient Recruitment
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 08, 2024
Details:
BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc disease.
Lead Product(s): BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2023
Details:
The Company intends to use the proceeds for its clinical trials with respect to its lead cell therapy candidate, BRTX-100, intended for the treatment of chronic lumbar disc disease, and for pre-clinical research and development with respect to its metabolic ThermoStem Program.
Lead Product(s): BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 11, 2023
Details:
BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc disease.
Lead Product(s): BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2023
Details:
BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc disease.
Lead Product(s): BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc disease.
Lead Product(s): BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Under the agreement, Northwell will participate in BioRestorative Therapies ongoing Phase 2 clinical trial, evaluating BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, targeting chronic lumber disc disease (cLDD).
Lead Product(s): BRTX-100
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BRTX-100
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Northwell Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 08, 2023
Details:
BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc disease.
Lead Product(s): BRTX-100
Therapeutic Area: Musculoskeletal Product Name: BRTX-100
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
ThermoStem® is a biorestorative therapies which uses brown adipose-derived (“brown fat”) stem cells that targets obesity and metabolic disorders, to generate new brown fat tissue.
Lead Product(s): Brown Adipose-derived Stem Cell
Therapeutic Area: Endocrinology Product Name: ThermoStem
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
The specific objective of the NIH grant is to enable the development and evaluation of the Company’s ThermoStem® program for the treatment of polycystic ovary syndrome (PCOS). Therapeutic brown adipocyte transplantation is an emerging and novel therapy for PCOS.
Lead Product(s): Brown Adipose-derived Stem Cells
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ThermoStem
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eunice Kennedy Shriver National Institute Of Child Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
